Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Lung Neoplasms 27Neoplasm Metastasis 26Carcinoma, Non-Small-Cell Lung 21Multiple Myeloma 18Urinary Bladder Neoplasms 16Breast Neoplasms 16Lymphoma 15Glioma 14Colorectal Neoplasms 14Pancreatic Neoplasms 13Lymphoma, Large B-Cell, Diffuse 13Carcinoma, Renal Cell 13Squamous Cell Carcinoma of Head and Neck 12Ovarian Neoplasms 12Melanoma 12Triple Negative Breast Neoplasms 11Glioblastoma 10Oropharyngeal Neoplasms 9Mouth Neoplasms 9Fallopian Tube Neoplasms 9Carcinoma 9Sarcoma 8Lymphoma, Non-Hodgkin 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Medulloblastoma 7Lymphoma, Follicular 7Laryngeal Neoplasms 7Carcinoma, Hepatocellular 7

Interventions

cabozantinib 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urachal adenocarcinoma × Magnetic Resonance Spectroscopy × 30 days × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡